Pleural Mesothelioma

Oncology
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Akesobio
AkesobioChina - Zhongshan
1 program
1
Cadonilimab Combined with chemotherapyPhase 21 trial
Active Trials
NCT06416930Not Yet Recruiting59Est. Jun 2029
M&
Merck & Co.RAHWAY, NJ
1 program
1
THOR-707Phase 21 trial
Active Trials
NCT04914897Terminated106Est. Oct 2024
Sanofi
SanofiPARIS, France
1 program
1
THOR-707Phase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AkesobioCadonilimab Combined with chemotherapy
Merck & Co.THOR-707

Clinical Trials (2)

Total enrollment: 165 patients across 2 trials

NCT06416930AkesobioCadonilimab Combined with chemotherapy

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Start: Jun 2024Est. completion: Jun 202959 patients
Phase 2Not Yet Recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Start: Sep 2021Est. completion: Oct 2024106 patients
Phase 2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space